Gouni-Berthold Ioanna, Berthold Heiner K, Chamberland John P, Krone Wilhelm, Mantzoros Christos S
Department of Internal Medicine II, University of Cologne, Cologne, Germany.
Clin Endocrinol (Oxf). 2008 Apr;68(4):536-41. doi: 10.1111/j.1365-2265.2007.03080.x. Epub 2007 Oct 31.
Statin therapy decreases cardiovascular morbidity and mortality, and ezetimibe, a novel cholesterol absorption inhibitor has both lipid-lowering and anti-atherosclerotic effects in animal models. As several adipokines, that is, adiponectin, high molecular weight (HMW) adiponectin, leptin and/or possibly resistin are involved in the pathogenesis of insulin resistance (IR), dyslipidaemia and atherosclerosis, we investigated whether ezetimibe and/or statin treatment may modulate serum concentrations of these four major adipokines.
One-centre, randomized, parallel three-group study in 72 healthy men [mean age 32 +/- 9 years, mean body mass index (BMI) 25.7 +/- 3.2 kg/m(2)].
Seventy-two healthy men. Each group of 24 subjects received a 14-day treatment with either ezetimibe (10 mg/day), simvastatin (40 mg/day) or their combination. Blood was drawn before and after the 14-day treatment period.
Lipid levels, IR indices, serum leptin, adiponectin, HMW adiponectin and resistin concentrations. Results Neither ezetimibe nor simvastatin or their combination had any effect on serum leptin, adiponectin, HMW adiponectin and resistin concentrations. Baseline leptin levels correlated positively, while adiponectin and HMW adiponectin negatively, with BMI. Leptin concentrations correlated negatively while adiponectin and HMW adiponectin positively with plasma high-density lipoprotein-cholesterol concentrations. Resistin concentrations were not associated with BMI, lipid levels or indicators of IR.
Treatment with ezetimibe, simvastatin or their combination does not alter circulating levels of adiponectin, leptin or resistin in adult healthy men.
他汀类药物治疗可降低心血管疾病的发病率和死亡率，而新型胆固醇吸收抑制剂依泽替米贝在动物模型中具有降脂和抗动脉粥样硬化作用。由于几种脂肪因子，即脂联素、高分子量（HMW）脂联素、瘦素和/或可能的抵抗素参与了胰岛素抵抗（IR）、血脂异常和动脉粥样硬化的发病机制，我们研究了依泽替米贝和/或他汀类药物治疗是否可调节这四种主要脂肪因子的血清浓度。
在72名健康男性中进行的单中心、随机、平行三组研究[平均年龄32±9岁，平均体重指数（BMI）25.7±3.2 kg/m²]。
72名健康男性。每组24名受试者接受为期14天的依泽替米贝（10 mg/天）、辛伐他汀（40 mg/天）或两者联合治疗。在14天治疗期前后采集血液。
血脂水平、IR指数、血清瘦素、脂联素、HMW脂联素和抵抗素浓度。结果依泽替米贝、辛伐他汀或其联合用药对血清瘦素、脂联素、HMW脂联素和抵抗素浓度均无影响。基线瘦素水平与BMI呈正相关，而脂联素和HMW脂联素与BMI呈负相关。瘦素浓度与血浆高密度脂蛋白胆固醇浓度呈负相关，而脂联素和HMW脂联素与血浆高密度脂蛋白胆固醇浓度呈正相关。抵抗素浓度与BMI、血脂水平或IR指标无关。
依泽替米贝、辛伐他汀或其联合治疗不会改变成年健康男性体内脂联素、瘦素或抵抗素的循环水平。
